CABA
NASDAQ
US
Cabaletta Bio, Inc. - Common Stock
$2,96
▲ +$0,28
(+10,45%)
Vol 2.1M
3
Skor Kualitas
fail
Pendapatan ✗
Laba Bersih ✗
>IPO ✗
Kap. Pasar
$210.8M
ROE
-107,1%
D/E
15,88
Beta
3,27
52W
$1–$4
Konsensus Wall Street
16 analis · Apr 20266
Beli Kuat
7
Beli
3
Tahan
0
Jual
0
Jual Kuat
81,2%
Peringkat Beli
Grafik Harga
Saham Serupa
IVVD
Invivyd Inc
$684.5M
IMRX
Immuneering Corp
$424.9M
PBYI
Puma Biotechnology Inc
P/E 8,1
$299.8M
DMAC
DiaMedica Therapeutics Inc
$414.5M
XOMA
Xoma Royalty Corp
P/E 15,2
$329.3M
IRD
Opus Genetics Inc
$138.6M
XFOR
X4 Pharmaceuticals Inc
$349.7M
NGNE
Neurogene Inc
$319.1M
FBRX
Forte Biosciences Inc
$341.6M
SRZN
Surrozen Inc
$193.7M
Pendapatan
Tingkat beat: 40,0%
Laporan Berikutnya
Mei 13, 2026
Estimasi EPS: $-0,41
| Kuartal | EPS Estimasi | EPS Aktual | Kejutan |
|---|---|---|---|
| Mar 2026 | $-0,41 | — | — |
| Des 2025 | $-0,47 | $-0,40 | +$0,07 |
| Sep 2025 | $-0,48 | $-0,44 | +$0,04 |
| Jun 2025 | $-0,66 | $-0,73 | $-0,07 |
Pendapatan & Laba Kuartalan
| Kuartal | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Pendapatan | — | — | — | — | — |
| Laba Bersih | -$30.6M | -$32.6M | -$35.9M | -$45.1M | -$44.9M |
Tren Fundamental
| Metrik | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -92.1% | -92.1% | -92.1% | -92.1% | -107.1% | -107.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 11.39 | 11.39 | 11.39 | 11.39 | 15.88 | 15.88 |
| Current Ratio | 4.78 | 4.78 | 4.78 | 4.78 | 3.60 | 3.60 |
Rasio Utama
ROA (TTM)
-83,0%
P/B
0,7
EPS (TTM)
$-2,51
CF/Share
$-1,64
52W High
$3,67
52W Low
$0,99
$0,99
Rentang 52 Minggu
$3,67
Kesehatan Keuangan
Arus Kas Bebas
-$34.6M
Utang Bersih
-$34.4M
Kas
$60.2M
Total Utang
$25.8M
Per tanggal Sep 30, 2025
Як CABA виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка CABA vs аналоги Biotechnology
P/E
—
▼
0%
di bawah
rekan
(18,8)
vs Rekan
vs Industri
Undervalued
P/S
—
▼
0%
di bawah
rekan
(12,9)
vs Rekan
vs Industri
Overvalued
P/B
0,7
▼
70%
di bawah
rekan
(2,5)
vs Rekan
vs Industri
Undervalued
Дивідендна дохідність
—
▼
0%
di bawah
rekan
(0,0%)
vs Rekan
vs Industri
Yield rendah
Прибутковість CABA vs аналоги Biotechnology
ROE
-107,1%
▼
59%
di bawah
rekan
(-67,3%)
vs Rekan
vs Industri
Lemah
Net margin
—
▼
0%
di bawah
rekan
(-286,8%)
vs Rekan
vs Industri
Tingkat atas
Валова маржа
—
▼
0%
di bawah
rekan
(78,6%)
vs Rekan
vs Industri
Sejajar
ROA
-83,0%
▼
78%
di bawah
rekan
(-46,7%)
vs Rekan
vs Industri
Lemah
Фінансове здоровʼя CABA vs аналоги Biotechnology
D/E ratio
15,9
▼
0%
di bawah
rekan
(0,0)
vs Rekan
vs Industri
Utang tinggi
Поточна ліквідність
3,6
▼
19%
di bawah
rekan
(4,4)
vs Rekan
vs Industri
Di bawah rata-rata
Beta
3,3
▲
237%
di atas
rekan
(1,0)
vs Rekan
vs Industri
Lebih volatil
Радар фундаменталів CABA
CABA
Median rekan
Industri
CABA прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
CABA vs аналоги: ключові метрики
Aktivitas Orang Dalam
NeutralPembelian
0
Penjualan
0
SIMON MARK
Director · Jan 21
11061 shs
NICHTBERGER STEVEN
Chief Executive Officer · Jan 21
45000 shs
TOMASELLO SHAWN CLINE
Director · Jan 21
22725 shs
CHANG DAVID J. M.D.
Officer · Jan 21
8800 shs
BOLLARD CATHERINE M.D.
Director · Jan 21
4405 shs
BINDER GWENDOLYN
Officer · Jan 21
11312 shs
GERARD MICHAEL
General Counsel · Jan 21
6600 shs
GAVEL STEVE
Officer · Jan 21
22170 shs
Terakhir 90 hari
Pemegang Terbesar
Top 5: 43,3%T. Rowe Price Investment Ma…
10,24%
$26.4M
Bain Capital Life Sciences …
10,05%
$25.9M
Jennison Associates LLC
9,25%
$23.9M
Adage Capital Partners GP L…
9,17%
$23.7M
Vanguard Group Inc
4,59%
$11.8M
Per tanggal Des 31, 2025
Berita Terbaru
Belum ada berita terkait